Suppr超能文献

澳大利亚教学医院肝癌筛查计划的效果和成本。

Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.

机构信息

Department of Liver Transplantation, Austin Hospital, Heidelberg, Victoria, Australia.

出版信息

J Gastroenterol Hepatol. 2010 May;25(5):951-6. doi: 10.1111/j.1440-1746.2009.06203.x.

Abstract

BACKGROUND AND AIM

Western countries are seeing an increasing prevalence of chronic viral hepatitis and a subsequent rise in the incidence of hepatocellular carcinoma (HCC). Screening patients at high risk of HCC has become standard practice. The aim of this study was to assess the efficacy and cost of screening high-risk individuals for HCC in an Australian tertiary hospital.

METHODS

A retrospective review was performed of all patients who underwent HCC screening at the Austin Hospital in Melbourne between 1 October 1998 and 31 August 2004. HCC screening was carried out in all cirrhotic patients and male non-cirrhotic patients with chronic hepatitis B virus. Screening consisted of 6-monthly alpha fetoprotein (AFP) measurements and ultrasounds (US). Outcomes of those who had HCC detected were followed up until 15 February 2007. Patients who had HCC satisfying the Milan criteria for liver transplantation were considered to have potentially curable tumor. Costs for the diagnostic tests were obtained from the 2004 Australian Medicare Benefits Schedule.

RESULTS

A total of 268 patient records were reviewed as part of the study. Chronic viral hepatitis accounted for 63% of the patients (n = 167). US screening was carried out at a median of 6.5 months and AFP measurements at a median of 4.0 months. HCC was detected in 22 patients (8.2%) at an incidence of 2.7% per year. These patients had a mean follow up of approximately 5.0 years after tumor detection. At the time of diagnosis, 17 patients had potentially curable tumor and 10 were alive at the conclusion of follow up. Of these 10 patients, six were successfully transplanted, three were successfully treated with radiological therapies and one was awaiting transplantation. The total cost of the screening program over the study period, including secondary investigations, was $A300,568. The cost per HCC detected was $13,662 and cost per potentially curable HCC was $17,680.

CONCLUSION

An effective HCC screening program can be provided through a multi-disciplinary outpatient facility in an Australian teaching hospital. Further stratification of the high risk patient cohort may improve the cost effectiveness of this screening program.

摘要

背景与目的

西方国家慢性病毒性肝炎的发病率不断上升,由此导致肝细胞癌(HCC)的发病率也有所上升。对 HCC 高危患者进行筛查已成为标准做法。本研究旨在评估在澳大利亚一所三级医院对高危个体进行 HCC 筛查的效果和成本。

方法

对 1998 年 10 月 1 日至 2004 年 8 月 31 日期间在墨尔本奥斯汀医院接受 HCC 筛查的所有患者进行了回顾性研究。对所有肝硬化患者和男性非肝硬化慢性乙型肝炎病毒患者进行 HCC 筛查。筛查包括每 6 个月进行一次甲胎蛋白(AFP)测量和超声(US)检查。对检测出 HCC 的患者进行随访,直至 2007 年 2 月 15 日。符合米兰肝移植标准的 HCC 患者被认为具有潜在可治愈的肿瘤。诊断性检查的费用是从 2004 年澳大利亚医疗保险福利计划中获得的。

结果

本研究共回顾了 268 份患者记录。慢性病毒性肝炎占患者的 63%(n=167)。US 筛查的中位数为 6.5 个月,AFP 测量的中位数为 4.0 个月。22 例患者(8.2%)检出 HCC,年发病率为 2.7%。这些患者在肿瘤检测后的平均随访时间约为 5.0 年。在诊断时,17 例患者具有潜在可治愈的肿瘤,10 例患者在随访结束时仍存活。在这 10 例患者中,6 例成功进行了移植,3 例成功接受了放射治疗,1 例正在等待移植。研究期间筛查计划的总费用(包括二级检查)为 300568 澳元。每检出 1 例 HCC 的成本为 13662 澳元,每检出 1 例潜在可治愈 HCC 的成本为 17680 澳元。

结论

在澳大利亚一所教学医院的多学科门诊机构中,可以提供有效的 HCC 筛查计划。对高危患者队列进行进一步分层可能会提高该筛查计划的成本效益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验